Research map: Low body weight as a risk factor for serious azathioprine-related adverse events in patients with rheumatic diseases

Back to the article

Papers in this map

  1. Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications · Arduino Aleksander Mangoni · 2003 · 1895 citations · Cited by this paper
  2. Recovery trajectories of TAFRO syndrome: a single-center case series highlighting prolonged thrombocytopenia and anasarca · 2026 · Related
  3. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management · Axel U Dignass · 2010 · 1499 citations · Cited by this paper
  4. Delayed glucocorticoid initiation is associated with lower stent removal rates in IgG4-related retroperitoneal fibrosis: a retrospective study · 2026 · Related
  5. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease · Marla C. Dubinsky · 2000 · 1004 citations · Cited by this paper
  6. Life-threatening refractory leukopenia in a patient with systemic lupus erythematosus successfully treated with rituximab · 2025 · Related
  7. Azathioprine and 6-Mercaptopurine in Crohn Disease · David C. Pearson · 1995 · 956 citations · Cited by this paper
  8. Association between Psoriasis Area and Severity Index Score and atherosclerotic risk in psoriasis patients using the Hisayama Score: a single-center retrospective study · 2026 · Related
  9. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia · Suk‐Kyun Yang · 2014 · 553 citations · Cited by this paper
  10. Systemic lupus erythematosus complicated by hydrocephalus and neuromyelitis optica spectrum disorder presenting with complex neuropsychiatric manifestations: a case report · 2026 · Related
  11. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 · Hiroshi Nakase · 2021 · 511 citations · Cited by this paper
  12. The role of immunoglobulin E in upper respiratory allergies: mechanisms and therapeutic strategies · 2025 · Related
  13. Role of Postreplicative DNA Mismatch Repair in the Cytotoxic Action of Thioguanine · PETER F. SWANN · 1996 · 411 citations · Cited by this paper
  14. Clinical feature of anti-myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis with cerebrospinal fluid anti-N-methyl-D-aspartate receptor antibody co-positivity: a single center case series · 2026 · Related
  15. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. · M De Silva · 1986 · 361 citations · Cited by this paper
  16. Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects disease severity · 2026 · Related
  17. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis · Eleana Ntatsaki · 2014 · 300 citations · Cited by this paper
  18. Muscle strength recovery in patients with idiopathic inflammatory myopathy with different myositis-specific autoantibodies · 2025 · Related
  19. Safety of Thiopurine Therapy in Inflammatory Bowel Disease · María Chaparro · 2013 · 296 citations · Cited by this paper
  20. Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management · Nicole Ann Pilch · 2020 · 186 citations · Cited by this paper
  21. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease · Ulf Hindorf · 2006 · 174 citations · Cited by this paper
  22. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD · Yoichi Kakuta · 2015 · 167 citations · Cited by this paper
  23. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study · for the MENDEL study group · 2018 · 128 citations · Cited by this paper
  24. Cytotoxic Mechanism of 6-Thioguanine: hMutSα, the Human Mismatch Binding Heterodimer, Binds to DNA Containing S6-Methylthioguanine · Timothy R. Waters · 1997 · 118 citations · Cited by this paper
  25. xAzathioprine therapy for patients with systemic lupus erythematosus · Mahmoud Abu‐Shakra · 2001 · 104 citations · Cited by this paper
  26. Clinical management of autoimmune hepatitis · Simon Pape · 2019 · 88 citations · Cited by this paper
  27. Azathioprine for treating rheumatoid arthritis · Maria Eugenia Suarez-Almazor · 2000 · 80 citations · Cited by this paper
  28. The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies · Meysam Zarezadeh · 2020 · 70 citations · Cited by this paper
  29. Population pharmacokinetic and pharmacogenetic analysis of 6‐mercaptopurine in paediatric patients with acute lymphoblastic leukaemia · Ahmed F. Hawwa · 2008 · 53 citations · Cited by this paper
  30. Early prediction of thiopurine‐induced hepatotoxicity in inflammatory bowel disease · Dennis R. Wong · 2016 · 46 citations · Cited by this paper
  31. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease · Shi Sum Poon · 2015 · 42 citations · Cited by this paper
  32. Safety Profile of Thiopurines in Crohn Disease · Yun Qiu · 2015 · 40 citations · Cited by this paper
  33. Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis · Jingru Tian · 2018 · 39 citations · Cited by this paper
  34. Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up · Qiong Fu · 2022 · 35 citations · Cited by this paper
  35. Reducing risk in thiopurine therapy · Anthony M. Marinaki · 2019 · 31 citations · Cited by this paper
  36. Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu's arteritis · Sema Kaymaz‐Tahra · 2024 · 13 citations · Cited by this paper
  37. Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity · Takato Maeda · 2021 · 12 citations · Cited by this paper
  38. Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study · Motoki Makuuchi · 2024 · 7 citations · Cited by this paper
  39. Questionnaire-based nationwide survey on the safety of azathioprine in Japanese patients with rheumatic diseases: a cross-sectional study · Shuhei Yoshida · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)